In the development of biopharmaceuticals, mostly based on large proteins, viruses, and cells, conventional approaches normally involve intuitive modifications of only a part or component of the complex bio-entities.
These fragmented approaches have often shown critical limitations as exemplified by unexpected serious side effects of the conventionally developed biopharmaceutical products.
In the development of biopharmaceuticals, mostly based on large proteins, viruses, and cells, conventional approaches normally involve intuitive modifications of only a part or component of the complex bio-entities.
These fragmented approaches have often shown critical limitations as exemplified by unexpected serious side effects of the conventionally developed biopharmaceutical products.
In the development of biopharmaceuticals, mostly based on large proteins, viruses, and cells, conventional approaches normally involve intuitive modifications of only a part or component of the complex bio-entities.
These fragmented approaches have often shown critical limitations as exemplified by unexpected serious side effects of the conventionally developed biopharmaceutical products.